

#3

Form PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 3504.246	SERIAL NO. To Be Assigned 09/678,851
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Offord, et al.	
		FILING DATE Herewith	GROUP 1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
<i>[Signature]</i>	P1	5,739,208	4/14/1998	Harris	525	54.1	6/7/1995
<i>[Signature]</i>	P2	5,672,662	9/30/1997	Harris, et al.	525	408	9/30/1997
<i>[Signature]</i>	P3	5,122,614	6/16/92	Zalipsky	548/520		6/16/1992
	P4						
	P5						
	P6						
	P7						
	P8						
	P9						
	P10						
	P11						

30922 U.S. PTO
09/678851
10/04/00

FOREIGN PATENT DOCUMENTS





















		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>[Signature]</i>	F1	96/34878	11/7/1996	WO	6			
<i>[Signature]</i>	F2	96/17935	6/13/1996	WO	6			
<i>[Signature]</i>	F3	0 605 963 A2	12/7/1993	EP	5			
	F4							

OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)

<i>[Signature]</i>	D1	Abuchowski, Abraham, et al., "Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol", <u>J.Biol.Chem.</u> , Vol. 252, No. 11, pp. 3578-3581 (1977)
<i>[Signature]</i>	D2	Alkhatib, Ghalib, et al., "CC CKR5: A RANTES, MIP-1 α , MIP-1 β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1", <u>Science</u> , Vol. 272, pp.1955-58 (1996)

EXAMINER B CELSA	DATE CONSIDERED 6/24/03
---------------------	----------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

Form PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 3504.246	SERIAL NO. To Be Assigned 09/678881
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Offord, et al.	
		FILING DATE Herewith	GROUP 1639
OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)			
	D3	Angiolillo, et al., "A Role for the Interferon-Inducible Protein 10 in Inhibition of Angiogenesis by Interleukin-12", <u>Annals NY Acad. Sci.</u> , Vol.795, pp.158-167 (1996)	
	D4	Arenzana-Seisdedos, Fernando, et al., "HIV Blocked by Chemokine Antagonist", <u>Nature</u> , Vol.383, p.400 (1996)	
	D5	Berger, et al., "A New Classification for HIV-1", <u>Nature</u> , Vol.391, p.240 (1998)	
	D6	Cairns, et al., "Chemokines and HIV-1 Second Receptors: The Therapeutic Connection", <u>Nature Med.</u> , Vol.4, No.5, pp.563-568 (1998)	
	D7	Chen, et al., "Genetically Divergent Strains of Simian Immunodeficiency Virus Use CCR5 as a Co-Receptor for Entry", <u>J.Virol.</u> , Vol.71, No.4, pp.2705-2714 (1997)	
	D8	Chesebro, et al., "Mapping of Independent V3 Envelope Determinants of Human Immunodeficiency Virus Type 1 Macrophage Tropism and Syncytium Formation in Lymphocytes", <u>J.Virol.</u> , Vol.70, No. 12, pp.9055-9059 (1996)	
	D9	Choe, et al., "The β -Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates", <u>Cell</u> , Vol.85, pp.1135-1148 (1996)	
	D10	Cocchi, et al., "Identification of RANTES, MIP-1 α , and MIP- β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells", <u>Science</u> , Vol. 270, pp.1811-1815 (1995)	
	D11	Cocchi, et al., "The V3 Domain of the HIV-1 gp 120 Envelope Glycoprotein is Critical for Chemokine-Mediated Blockade of Infection", <u>Nature Med.</u> , Vol. 2, No.11, pp. 1244-1247 (1996)	
	D12	Connor, et al., "Increased Viral Burden and Cytopathicity Correlate Temporally with CD4+ T-Lymphocyte Decline and Clinical Progression in Human Immunodeficiency Virus Type 1-Infected Individuals", <u>J.Virol.</u> , Vol.67, No.4, pp.1772-1777 (1993)	
	D13	Danesi, et al., "Inhibition of Experimental Angiogenesis by the Somatostatin Analogue Octreotide Acetate (SMS 201-995)", <u>Clin.Cancer Res.</u> , Vol.3, pp.265-272 (1997)	
	D14	Datema, et al., "Antiviral Efficacy in Vivo of the Anti-Human Immunodeficiency Virus Bicyclam SDZ SID 791 (JM3100), an Inhibitor of Infectious Cell Entry", <u>Antimicrob. Agents and Chemo.</u> , Vol. 40, No3., pp.750-754 (1996)	
	D15	Dawson, et al., "Synthesis of Proteins by Native Chemical Ligation", <u>Science</u> , Vol. 266, pp. 776-779 (1994)	
	D16	Deng, et al., "Identification of a Major Co-Receptor for Primary Isolates of HIV-1", <u>Nature</u> , Vol. 381, pp.661-666 (1996)	
	D17	Doranz, et al., "A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β -Chemokine Receptors CKR-5, CKR-3, and CKR-2B as Fusion Cofactors", <u>Cell</u> , Vol. 85, pp.1149-1158 (1996)	
	D18	Friedlander, et al. "Definition of Two Angiogenic Pathways by Distinct α , Integrins", <u>Science</u> , Vol.270, pp.1500-1502 (1995)	
	D19	Gao, et al., "Structure and Functional Expression of the Human Macrophage Inflammatory Protein 1 α /RANTES Receptor", <u>J.Exp.Med.</u> , Vol. 177, pp. 1421-1427 (1993)	
	D20	Gauduin, et al., "Passive Immunization With a Human Monoclonal Antibody Protects hu-PBL-SCID Mice Against Challenge by Primary Isolates of HIV-1", <u>Nat.Med.</u> , Vol. 3, No.12, pp.1389-1393 (1997)	
	D21	Hojo, Hironobu and Aimoto, Saburo, "Polypeptide Synthesis Using the S-Alkyl Thioester of a Partially Protected Peptide Segment. Synthesis of the DNA-Binding Domain of c-Myb Protein (142-193)-NH ₂ ", <u>Bull.Chem.Soc.Jpn.</u> , Vol. 64, pp. 111-117 (1991)	
EXAMINER 		DATE CONSIDERED 6/24/03	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

Form PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. <div style="text-align: center; font-weight: bold;">3504.246</div>	SERIAL NO. <div style="text-align: center; font-weight: bold;">To Be Assigned</div> <div style="text-align: center; font-size: 1.2em;">09/678, 851</div>
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Offord, et al.	
		FILING DATE <div style="text-align: center; font-weight: bold;">Herewith</div>	GROUP <div style="text-align: center; font-size: 1.2em;">1139</div>

OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)	
D22	Jose, et al., "Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation", <u>J.Exp.Med.</u> , Vol.179, pp. 881-887 (1994)
D23	Mack, et al., "Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity", <u>J.Exp.Med.</u> , Vol. 187, No.8, pp. 1215-1224 (1998)
D24	Mosier, et al., "Transfer of a Functional Human Immune System to Mice With Severe Combined Immunodeficiency", <u>Nature</u> , Vol. 335, pp. 256-259 (1988)
D25	Mosier, et al., "Human Immunodeficiency Virus Infection of Human-PBL-SCID Mice", <u>Science</u> , Vol. 251, pp.791-794 (1991)
D26	Mosier, et al., "Rapid Loss of CD4+ T Cells in Human-PBL-SCID Mice by Noncytopathic HIV Isolates", <u>Science</u> , Vol. 260, pp. 689-692 (1993)
D27	Mosier, Donald, "Human Immunodeficiency Virus Infection of Human Cells Transplanted to Severe Combined Immunodeficient Mice", <u>Adv.in Immun.</u> , Vol. 63, pp. 79-125 (1996)
D28	McKnight, et al., "HIV-2 and SIV Infection of Nonprimate Cell Lines Expressing Human CD4: Restrictions to Replication at Distinct Stages", <u>Virology</u> , Vol. 201, pp.8-18 (1994)
D29	Neote, et al., "Molecular Cloning, Functional Expression, and Signaling Characteristics of a C-C Chemokine Receptor", <u>Cell</u> , Vol. 72, pp.415-425 (1993)
D30	Oikawa, et al., "Angiogenic Factor of a rat Mammary Tumor Cell Line (RMT-1) (I). Secretion of two Distinct Angiogenic Factors Into Serum-Free Conditioned Medium by RMT-1 Cells", <u>Cancer Lett.</u> , Vol. 59, pp. 57-66 (1991)
D31	Parren, et al., "Protection Against HIV-1 Infection in hu-PBL-SCID Mice by Passive Immunization With a Neutralizing Human Monoclonal Antibody Against the gp120 CD4-Binding Site", <u>AIDS</u> , Vol.9, No.6, pp. 1-6 (1995)
D32	Paxton, et al., "Reduced HIV-1 Infectability of CD4+ Lymphocytes From Exposed-Uninfected Individuals: Association With Low Expression of CCR5 AND High Production of β -Chemokines", <u>Virology</u> , Vol. 244, pp.66-73 (1998)
D33	Picchio, et al., "Chemokine Receptor CCR5 Genotype Influences the Kinetics of Human Immunodeficiency Virus Type 1 Infection in Human PBL-SCID Mice", <u>J.Virol.</u> , Vol. 71, No. 9, pp 7124-7127 (1997)
D34	Picchio, et al., "The Cell Tropism of Human Immunodeficiency Virus Type 1 Determines the Kinetics of Plasma Viremia in SCID Mice Reconstituted With Human Peripheral Blood Leukocytes", <u>J.Virol.</u> , Vol. 72, No.3, pp.2002-2009 (1998)
D35	Proudfoot, et al., "Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist", <u>J.Biol.Chem.</u> , Vol. 271, No. 5, pp.2599-2603 (1996)
D36	Risau, Werner, "Mechanisms of Angiogenesis", <u>Nature</u> , Vol. 386, pp.671-674 (1997)
D37	Schnolzer, et al., "In situ neutralization in Boc-chemistry Solid Phase Peptide Synthesis", <u>J.Peptide Protein Res.</u> , Vol. 40, pp. 180-193 (1992)
D38	Schuitemaker, et al., "Monocytotropic Human Immunodeficiency Virus Type 1 (HIV-1) Variants Detectable in all Stages of HIV-1 Infection Lack T-Cell Line Tropism and Syncytium-Inducing Ability in Primary T-Cell Culture", <u>J.Virol.</u> , Vol. 65, No.1, pp. 356-363 (1991)
D39	Simmons, et al., "Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist", <u>Science</u> , Vol.276, PP.276-279 (1997)

EXAMINER <div style="font-size: 1.5em; font-family: cursive;">B. Carr</div>	DATE CONSIDERED <div style="font-size: 1.5em; font-family: cursive;">6/24/03</div>
--	---

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

Form PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 3504.246	SERIAL NO. To Be Assigned 09/678,851
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Offord, et al.	
		FILING DATE Herewith	GROUP 1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	P1					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	F1						

OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)

D1	Noso, Norio, et al., "Identification of a N-Terminally Truncated Form of the Chemokine RANTES and Granulocyte-Macrophage Colony-Stimulating Factor as Major Eosinophil Attractants Released by Cytokine-Stimulated Dermal Fibroblasts", <u>Journal of Immunology</u> , Vol. 156, no.5, pgs. 1946-1953 (1996)
D2	International Search Report for PCT/US98/18204
EXAMINER B Cera	DATE CONSIDERED 6/24/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.